These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35680984)

  • 21. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
    Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
    Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.
    Serresi M; Gargiulo G; Proost N; Siteur B; Cesaroni M; Koppens M; Xie H; Sutherland KD; Hulsman D; Citterio E; Orkin S; Berns A; van Lohuizen M
    Cancer Cell; 2016 Jan; 29(1):17-31. PubMed ID: 26766588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
    Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
    Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA MALAT1 promotes epithelial-to-mesenchymal transition of esophageal cancer through Ezh2-Notch1 signaling pathway.
    Chen M; Xia Z; Chen C; Hu W; Yuan Y
    Anticancer Drugs; 2018 Sep; 29(8):767-773. PubMed ID: 29916899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.
    Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X
    Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
    Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
    Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic network of EZH2/SFRP1/Wnt in the epithelial-mesenchymal transition of laryngeal carcinoma cells.
    Chen W; Wang HT; Ji JF; Wang ZY; Shi T; Wu MH; Yu PJ
    Neoplasma; 2022 May; 69(3):680-690. PubMed ID: 35400167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased miR-124 contributes to the epithelial-mesenchymal transition phenotype formation of lung adenocarcinoma cells via targeting enhancer of zeste homolog 2.
    Wu J; Li L; Zhang Y; Zhu J
    Pathol Res Pract; 2020 Jun; 216(6):152976. PubMed ID: 32370988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity.
    Skrypek N; Goossens S; De Smedt E; Vandamme N; Berx G
    Trends Genet; 2017 Dec; 33(12):943-959. PubMed ID: 28919019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
    Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition.
    Battistelli C; Cicchini C; Santangelo L; Tramontano A; Grassi L; Gonzalez FJ; de Nonno V; Grassi G; Amicone L; Tripodi M
    Oncogene; 2017 Feb; 36(7):942-955. PubMed ID: 27452518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
    Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
    FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value.
    Meseure D; Vacher S; Alsibai KD; Nicolas A; Chemlali W; Caly M; Lidereau R; Pasmant E; Callens C; Bieche I
    Mol Cancer Res; 2016 Jul; 14(7):623-33. PubMed ID: 27102007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.
    Pastushenko I; Mauri F; Song Y; de Cock F; Meeusen B; Swedlund B; Impens F; Van Haver D; Opitz M; Thery M; Bareche Y; Lapouge G; Vermeersch M; Van Eycke YR; Balsat C; Decaestecker C; Sokolow Y; Hassid S; Perez-Bustillo A; Agreda-Moreno B; Rios-Buceta L; Jaen P; Redondo P; Sieira-Gil R; Millan-Cayetano JF; Sanmatrtin O; D'Haene N; Moers V; Rozzi M; Blondeau J; Lemaire S; Scozzaro S; Janssens V; De Troya M; Dubois C; Pérez-Morga D; Salmon I; Sotiriou C; Helmbacher F; Blanpain C
    Nature; 2021 Jan; 589(7842):448-455. PubMed ID: 33328637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Is Required for Uterine Epithelial Integrity.
    Fang X; Ni N; Lydon JP; Ivanov I; Bayless KJ; Rijnkels M; Li Q
    Am J Pathol; 2019 Jun; 189(6):1212-1225. PubMed ID: 30954472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.